On May 22, 2013, the Company entered into a letter of intent to in-license a Phase 2 drug candidate in L-Dopa-Induced Dyskinesia Parkinson’s Disease from an undisclosed third party. Once licensed the Company intends to initiate a Phase 2b clinical trial within 12 months.